OscarBoutrosLahoudMD

PubMed

• 1 citations
  CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
  Ross S Firestone, Devin McAvoy, Tala Shekarkhand, Edith Serrano, Issam Hamadeh, Alice Wang, Menglei Zhu, Wei Ge Qin, Dhwani Patel, Carlyn R Tan, Malin Hultcrantz, Sham...> ;Blood Advances. 2024 Apr 9
• BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cel...
  Robert Stuver, Agrima Mian, Samantha Brown, Sean Devlin, Paolo F Caimi, Stephanie Chinapen, Parastoo Dahi, Robert Dean, Zachary D Epstein-Peterson, Brian Hill, Steven ...> ;American Journal of Hematology. 2024 Mar 25
• Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
  Lesokhin, A., Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B., Nishimura, N., Farzana, T., Rueda, C., Chung, D., Landau, H., Lahoud, O., Scordo, M., ...> ;Research Square. 2024 Feb 7
• 2 citations
  Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation wit...
  Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomas...> ;British Journal of Haematology. 2023 Dec 1
• Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma.
  Parastoo B Dahi, Sheila Kenny, Jessica Flynn, Sean M Devlin, Josel D Ruiz, Stephanie A Chinapen, Oscar B Lahoud, Matthew J Matasar, Craig H Moskowitz, Miguel-Angel Per...> ;Leukemia & Lymphoma. 2023 Dec 1
• 2 citations
  The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantation.
  Shlomo Elias, Samantha Brown, Sean M Devlin, Juliet N Barker, Christina Cho, David J Chung, Parastoo B Dahi, Sergio Giralt, Boglarka Gyurkocza, Ann A Jakubowski, Oscar...> ;British Journal of Haematology. 2023 Dec 1
• Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
  Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, D...> ;Blood Cancer Journal. 2023 Jul 25
• 1 citations
  Retrospective characterization of nodal marginal zone lymphoma.
  Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin,...> ;Blood Advances. 2023 Sep 12
• 1 citations
  Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort ...
  Neha Korde, Elizabet Tavitian, Donna Mastey, Joseph Lengfellner, Gil Hevroni, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Eric L Smith, Malin Hultcra...> ;Eclinicalmedicine. 2023 Mar 1
• 1 citations
  Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma.
  Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, D...> ;Research Square. 2023 Feb 24
• 14 citations
  Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma ...
  Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Tadeusz Kubicki, Paweł Robak, Adam Walter-Croneck, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzyszto...> ;The Lancet. Oncology. 2023 Feb 1
• Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
  Matthew J Pianko, Timothy Tiutan, Andriy Derkach, Jessica Flynn, Steven P Salvatore, Insara Jaffer-Sathick, Adriana C Rossi, Oscar Lahoud, Malin Hultcrantz, Urvi A Sha...> ;American Journal of Hematology. 2023 Mar 1
• 1 citations
  Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era.
  David Qualls, Brandon S Imber, Michelle Okwali, Paul A Hamlin, Anita Kumar, Oscar B Lahoud, Matthew J Matasar, Ariela Noy, Colette Owens, Andrew D Zelenetz, Victoria S...> ;British Journal of Haematology. 2023 Feb 1
• 2 citations
  Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation.
  Michael Scordo, Leah J Gilbert, Danielle M Hanley, Jessica R Flynn, Sean M Devlin, Linh K Nguyen, Josel D Ruiz, Gunjan L Shah, Craig S Sauter, David J Chung, Heather J...> ;Blood Advances. 2023 Apr 25
• 2 citations
  Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study.
  Sham Mailankody, Meghan Salcedo, Elizabet Tavitian, Miranda Burge, Neha Korde, Hani Hassoun, Alexander Lesokhin, Oscar Lahoud, Eric Smith, Malin Hultcrantz, Carlyn Tan...> ;Leukemia & Lymphoma. 2022 Nov 1
• A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
  Karthik Nath, Tala Shekarkhand, Meghan Salcedo, Andriy Derkach, Siobhan Rueda, Aisara Chansakul, Malin Hulcrantz, Neha Korde, Urvi A Shah, Carlyn Tan, David J Chung, O...> ;Leukemia & Lymphoma. 2022 Dec 1
• 13 citations
  Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
  Urvi A Shah, Kylee H Maclachlan, Andriy Derkach, Meghan Salcedo, Kelly Barnett, Julia Caple, Jenna Blaslov, Linh Tran, Amanda Ciardiello, Miranda Burge, Tala Shekarkha...> ;Clinical Cancer Research. 2022 Dec 1
• 1 citations
  Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis.
  Cara A Rosenbaum, Umut Özbek, Larysa Sanchez, Jonathan Lagdameo, Alex Abrahams, Hani Hassoun, Oscar Lahoud, Ruben Niesvizky, Heather J Landau, Keren Osman> ;Blood Advances. 2022 Sep 27
• 3 citations
  A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
  Michael Scordo, Gunjan L Shah, Peter A Adintori, Andrea Knezevic, Sean M Devlin, Marissa L Buchan, Elaina V Preston, Andrew P Lin, Natasia T Rodriguez, Caroline A Cari...> ;Cancer. 2022 Nov 1
• 5 citations
  AA amyloidosis associated with cancers.
  Joyita Bharati, Oscar B Lahoud, Kenar D Jhaveri, Hassan Izzedine> ;Nephrology, Dialysis, Transplantation. 2023 May 31
• 1 citations
  Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted appro...
  Oscar B Lahoud, Heather Landau, James Nguyen, Sean Devlin, Nikoletta Lendvai, Jonathan Weltz, Tumininu Ayorinde, David J Chung, Alexander M Lesokhin, Tarun Kewalramani...> ;Leukemia & Lymphoma. 2022 Sep 1
• 2 citations
  Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
  Malin Hultcrantz, Even H Rustad, Venkata Yellapantula, Allison Jacob, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alexander M Lesokhin, Hani Hassoun, Eric L Smith,...> ;Clinical Cancer Research. 2022 May 13
• Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation.
  Parastoo B Dahi, Andrew Lin, Michael Scordo, Jessica R Flynn, Sean M Devlin, Josel D Ruiz, Lauren DeRespiris, Dean Carlow, Christina Cho, Oscar B Lahoud, Miguel-Angel ...> ;Transplantation and Cellular Therapy. 2022 Aug 1
• 16 citations
  Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.
  Oscar B Lahoud, Sean M. Devlin, Molly Maloy, Lindsey E. Roeker, Parastoo B. Dahi, Doris M. Ponce, Boglarka Gyurkocza, Guenther Koehne, James W. Young, Hugo Castro-Mala...> ;Blood Advances. 2021 Jul 27
• 68 citations
  Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
  Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santa...> ;Journal of Clinical Oncology. 2021 Jun 25
• Join now to see all

Abstracts/Posters

• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
  Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
  Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
  Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018